Solara Reports Record Q2'27 Results with EBITDA Surging 118% YoY
Solara Active Pharma Sciences Ltd 路 Press Release 路 16 Oct 2026, 7:18 pm
Solara Reports Record Q2'27 Results with EBITDA Surging 118% YoY Solara Active Pharma Sciences reported a strong Q2'27 performance, with revenue growing 33% YoY and 9% QoQ to INR 4,178 Mn. EBITDA surged 118% YoY and 21% QoQ to INR 769 Mn, expanding margins by 720 bps YoY to 18.4%. PAT turned around to INR 285 Mn from a loss of INR 101 Mn in Q2'26. Growth was driven by the base API business (revenue up 37% YoY to INR 3,273 Mn) and Ibuprofen narrowing EBITDA losses to INR 2 Mn. Net debt fell 19% to INR 5,000 Mn.
Original exchange filing (PDF)
More announcements from Solara Active Pharma Sciences Ltd
- Transcript of Earnings Conference call pertaining to financial results of the Company for the quarter ended September 30, 2026 路 23 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding the dispatch of Final Reminder -cum-Forfeiture Notice for the payment of outstanding call money to the holders .... 路 18 Oct 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 路 17 Oct 2026
- Audio recordings of Q2 FY27 earnings call conducted on October 16, 2026, for the quarter ended September 30, 2026 路 17 Oct 2026
- Solara Active Pharma Sciences Limited has informed the exchange about the Statement of Deviation/Variation in utilization of funds raised though Rights issue for the quarter ended September 30 2026 路 16 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding grant of 470000 options under Solara Employee Stock Option Plan 2024 路 16 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding allotment of 8,300 Equity shares pursuant to exercise of ESOP options. 路 16 Oct 2026
- Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter .... 路 16 Oct 2026
